Literature DB >> 8006323

Effects of ritanserin, a novel serotonin-S2 receptor antagonist, on the secretion of pituitary hormones in normal humans.

D Tepavcević1, Z Giljević, M Korsić, S Halimi, E Suchanek, T Jelić, I Aganović, B Kozić, V Plavsić.   

Abstract

The availability of a new potent and selective serotonin-S2 antagonist, ritanserin (RIT), encouraged us to further investigate the effect of serotonin on the basal secretion of anterior pituitary hormones in normal humans. Administered in a single 30-mg dose to group 1 consisting of 10 normal women, RIT failed to affect the baseline LH, FSH, GH or TSH levels. In group 2 consisting of 20 normal subjects (ten males and ten females), the same dose of RIT decreased in parallel both ACTH and cortisol levels but only at 180 min. Group 3 consisting of 8 normal men was studied on three separate occasions seven days apart: each subject received graded doses of 10 mg, 20 mg and 30 mg RIT. The mean baseline PRL concentration at 180 min as well as the net integrated area under the hormone curve (nAUC) decreased only after the highest dose, while the baseline cortisol concentrations at 180 min as well as the corresponding nAUC values displayed a clear dose-dependent response. The findings indicated the serotonin-S2 receptors to be only partially involved in the basal secretion of ACTH in normal humans.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8006323     DOI: 10.1007/BF03344953

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  25 in total

1.  The role of serotonin (5-HT) in the control of TSH and prolactin release in euthyroid subjects as assessed by the administration of ketanserin (5-HT2 antagonist) and zimelidine (5-HT re-uptake inhibitor).

Authors:  B P O'Malley; P E Jennings; N Cook; D B Barnett; F D Rosenthal
Journal:  Psychoneuroendocrinology       Date:  1984       Impact factor: 4.905

2.  Receptor binding profile of R 41 468, a novel antagonist at 5-HT2 receptors.

Authors:  J E Leysen; F Awouters; L Kennis; P M Laduron; J Vandenberk; P A Janssen
Journal:  Life Sci       Date:  1981-03-02       Impact factor: 5.037

3.  Effect of cyproheptadine on TRH-stimulated prolactin and TSH release in man.

Authors:  A C Egge; A D Rogol; M M Varma; R M Blizzard
Journal:  J Clin Endocrinol Metab       Date:  1977-01       Impact factor: 5.958

4.  Effect of cyproheptadine on the spontaneous diurnal variations of plasma ACTH-cortisol and ACTH-GH secretion induced by l-dopa.

Authors:  G Delitala; A Masala; S Alagna; L Devilla
Journal:  Biomedicine       Date:  1975-12-20

5.  Ketanserin without effects on basal anterior pituitary hormone secretion in healthy subjects.

Authors:  A Gordin; P Mustajoki; R Pelkonen
Journal:  J Endocrinol Invest       Date:  1985-02       Impact factor: 4.256

6.  Receptor-binding properties in vitro and in vivo of ritanserin: A very potent and long acting serotonin-S2 antagonist.

Authors:  J E Leysen; W Gommeren; P Van Gompel; J Wynants; P F Janssen; P M Laduron
Journal:  Mol Pharmacol       Date:  1985-06       Impact factor: 4.436

7.  The effect of ketanserin, a specific serotonin antagonist on the PRL, GH, ACTH and cortisol responses to hypoglycaemia in normal subjects.

Authors:  R W Prescott; P Kendall-Taylor; D R Weightman; M J Watson; W A Ratcliffe
Journal:  Clin Endocrinol (Oxf)       Date:  1984-02       Impact factor: 3.478

8.  The effect of a 5-HT antagonist, ketanserin, on blood pressure, the renin-angiotensin system and sympathoadrenal function in normal man.

Authors:  C Zoccali; J R Zabludowski; C G Isles; G D Murray; G C Inglis; J I Robertson; R Fraser; S G Ball
Journal:  Br J Clin Pharmacol       Date:  1983-09       Impact factor: 4.335

9.  Inhibitory effect of ritanserin on the 5-hydroxytryptophan-mediated cortisol, ACTH and prolactin secretion in humans.

Authors:  M A Lee; J F Nash; M Barnes; H Y Meltzer
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

10.  Effects of cyproheptadine on insulin-induced hypoglycaemia secretion of PRL, GH and cortisol.

Authors:  O A Kletzky; R P Marrs; J T Nicoloff
Journal:  Clin Endocrinol (Oxf)       Date:  1980-09       Impact factor: 3.478

View more
  3 in total

1.  Ziprasidone decreases cortisol excretion in healthy subjects.

Authors:  Andreas Meier; Anna-Catharina Neumann; Wolfgang Jordan; Gerald Huether; Andrea Rodenbeck; Eckart Rüther; Stefan Cohrs
Journal:  Br J Clin Pharmacol       Date:  2005-09       Impact factor: 4.335

2.  Effects of ritanserin, a specific serotonin-S2 receptor antagonist, on the release of anterior pituitary hormones during insulin-induced hypoglycemia in normal humans.

Authors:  D Tepavcević; Z Giljević; I Aganović; M Korsić; S Halimi; E Suchanek; T Jelić; B Kozić; V Plavsić
Journal:  J Endocrinol Invest       Date:  1995-06       Impact factor: 4.256

3.  Activation of the JAK-STAT pathway by olanzapine is necessary for desensitization of serotonin2A receptor-stimulated phospholipase C signaling in rat frontal cortex but not serotonin2A receptor-stimulated hormone release.

Authors:  R K Singh; C Jia; F Garcia; G A Carrasco; G Battaglia; N A Muma
Journal:  J Psychopharmacol       Date:  2009-03-20       Impact factor: 4.153

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.